Previous Article | Next Article ![]()
Journal of Virology, October 2001, p. 9357-9366, Vol. 75, No. 19
Laboratory of Molecular Genetics, National
Institute of Child Health and Human
Development,1 and Laboratory of
Molecular Microbiology, National Institute of Allergy and Infectious
Diseases,2 Bethesda, Maryland 20892, and
HIV Drug Resistance Program, Frederick Cancer Research and
Development Center, National Cancer Institute, Frederick, Maryland
217023
Received 21 March 2001/Accepted 23 June 2001
A group of conserved hydrophobic residues faces the interior of the
coiled-coil-like structure within the N-terminal domain of the human
immunodeficiency virus type 1 (HIV-1) capsid protein (CA). It has been
suggested that these residues are important for maintaining stable
structure and functional activity. To investigate this possibility, we
constructed two HIV-1 clones, in which Trp23 or Phe40 was changed to
Ala. We also constructed a third mutant, D51A, which has a mutation
that destroys a salt bridge between Pro1 and Asp51. All three mutants
are replication defective but produce virus particles. Mutant virions
contain all of the viral proteins, although the amount and stability of
CA are decreased and levels of virion-associated integrase are reduced.
The mutations do not affect endogenous reverse transcriptase activity;
however, the mutants are blocked in their ability to initiate reverse
transcription in infected cells and no minus-strand strong-stop DNA is
detected. The defect in reverse transcription is associated with
striking defects in the morphology of mutant virus cores, as determined by transmission electron microscopy. Our data indicate that the mutations made in this study disrupt CA structure and prevent proper
maturation of virus cores. We propose that this results in a defect in
core stability or in an early postentry event preceding reverse transcription.
The Gag polyprotein of human
immunodeficiency virus type 1 (HIV-1) is essential for virus assembly
and release and, in fact, is the only viral protein that is required
(reviewed in references 9, 43, 49, and 55). During or
shortly after the budding of virus particles, Gag is cleaved by the
viral protease to yield the mature structural proteins, i.e., matrix
(MA, p17), capsid (CA, p24), nucleocapsid (NC, p7), and p6 (25,
36; reviewed in references 9, 48, and 49). Gag
processing induces a structural rearrangement of the individual
proteins in a process known as "maturation," which results in the
conversion of immature particles to mature, infectious virions. For
example, upon cleavage at the MA-CA junction, refolding at the N
terminus of CA leads to the formation of a new The interior of the viral core consists of a ribonucleoprotein complex
containing genomic RNA; the tRNA Analysis by nuclear magnetic resonance spectroscopy (20)
and X-ray crystallography (38) revealed that the
N-terminal region is composed of five long
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.19.9357-9366.2001
Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants
That Exhibit Aberrant Core Morphology and Are Blocked in Initiation
of Reverse Transcription in Infected Cells
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-hairpin/helix
structure that is stabilized by formation of a buried salt bridge
between the charged amino terminus of Pro1 and the carboxylate of Asp51
(20, 51). These rearrangements are associated with a
dramatic morphological change that transforms the immature spherical,
electron-lucent core to one that is electron dense and conical
(18, 22, 23, 51; for earlier citations, see references
43, 49, and 55). In addition, the nucleic acid chaperone
activity of mature NC (reviewed in reference 41) catalyzes
refolding of genomic RNA to form a thermostable dimer (6, 14,
15).

-helices (I, II, III, IV,
and VII [20] or A, B, C, D, and G [38])
and two shorter helices (V and VI [20] or E and F
[38]), two
-hairpins, and an exposed proline-rich loop (Fig. 1). On the basis of a
multiple-sequence alignment, Momany et al. (38) identified
a group of conserved hydrophobic residues that faces the interior of
the coiled-coil-like structure formed by the five long
-helices, and
it was suggested that these residues are important for maintaining the
stability of the structure (38). The proline-rich loop is
the binding site of host cellular protein cyclophilin A (CypA)
(16), a peptidyl-prolyl cis-trans isomerase
that is incorporated into virions and that is required for production
of infectious virions (8, 45).

View larger version (43K):
[in a new window]
FIG. 1.
Ribbon representation showing a front view of the
N-terminal core domain of HIV-1 CA. The
-hairpin structure, CypA
binding loop, and seven
-helices are labeled (20, 38).
Note that the helices are numbered as described by Gitti et al.
(20). The three residues mutated in this study, W23, F40,
and D51, are located in helices I, II, and III, respectively. The
diagram was generated with Molscript (32).
The N-terminal domain of CA plays a major role in the early steps of
the virus life cycle. Interestingly, linker insertions and deletions in
this region (5, 39, 40, 52) are compatible with efficient
assembly of virus particles, and as many as 56 residues in this domain
can be deleted without an adverse effect on particle formation
(52). However, mutations in the N-terminal domain often
affect proper virion core formation and virus replication (5, 7,
39, 40, 51, 52). Indeed, aberrant core morphology is
consistently associated with loss of infectivity (5, 7, 39,
51), although the converse is not necessarily true. (For example, CA mutants with substitutions in residues in the proline-rich CypA binding loop are poorly infectious but exhibit normal core morphology [3, 7, 54].) Some studies have also shown
that formation of abnormal cores is associated with a defect in reverse transcription in infected cells (7, 39). However, whether the defect represents a block in the very first step in the process, i.e., synthesis of minus-strand strong-stop DNA [(
) SSDNA], was not
tested. Defects in reverse transcription postentry have also been
described for Rous sarcoma virus (4a) and Moloney murine leukemia virus
(MLV) (2a) CA mutants.
The goal of the present work was to investigate the impact of specific N-terminal CA mutations on the ability of HIV-1 virions to undergo reverse transcription in the infected cell and the possible correlation with virus core assembly. Our approach was to make single alanine substitutions rather than deletions or insertions, since point mutations might be less likely to result in drastic perturbation of CA secondary and tertiary structures. Mutations were made in two aromatic residues, Trp23 (helix I; Fig. 1) and Phe40 (helix II; Fig. 1), which are among the conserved hydrophobic residues identified by Momany et al. (38) (see above). For comparison, we also constructed another mutant, D51A. This mutant can no longer form the Pro1-Asp51 salt bridge and was previously shown to produce noninfectious particles having an abnormal core (51); however, the ability of the D51A mutant to make viral DNA during infection was not assessed.
Here, we demonstrate that all three mutants produce essentially normal
levels of virus particles but are unable to replicate in single-cycle
and long-term culture assays. These particles also exhibit abnormal
core structures, as determined by transmission electron microscopy.
Although the endogenous RT activity of the mutants is not impaired,
none of the viral DNA products normally made during reverse
transcription, including (
) SSDNA, can be detected in cells infected
with these mutants. Taken together, our findings indicate that assembly
of virions with aberrant core structures leads to a defect in
initiation of reverse transcription and loss of infectivity. We
conclude that aromatic residues Trp23 and Phe40 and acidic residue
Asp51 are required for formation of functional virus cores.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials. Competent STBL2 cells were obtained from Life Technologies Inc. (Rockville, Md.). [35S]cysteine (500 to 1,000 Ci/mmol) was purchased from American Radiolabeled Chemicals, Inc. (St. Louis, Mo.).
Plasmids. The plasmids used for this work were the HIV-1 infectious proviral clone pNL4-3 (2) and env-negative subclone pNL4-3KFS, which has a frameshift mutation in the env coding region (10, 13). The parent pNL4-3KFS clone is sometimes referred to as "wild type" since the CA domain in Gag has the wild-type sequence. The envelope vector is amphotropic MLV envelope glycoprotein expression plasmid pSV-A-MLVenv (33).
Cells.
293T, HeLa, and HeLa CD4-LTR/
-gal indicator cells
(29) (CD4-positive HeLa indicator cells) were maintained
in Dulbecco's modified Eagle's medium; H9 and CEM (12D7) CD4-positive
T-lymphocyte cell lines were cultured in RPMI 1640 medium. All media
contained 10% fetal bovine serum, 2 mM glutamine, and antibiotics.
Mutagenesis and cloning. The strategy for introducing mutations into the CA domain of Gag in pNL4-3 (2) or pNL4-3KFS (10, 13) by PCR-based site-directed mutagenesis has been described previously (44). Specific details on the procedures used to construct the W23A, F40A, and D51A mutations are available upon request. To avoid undesirable deletion or recombination events, plasmid DNAs were propagated in STBL2 cells at 30°C. The sequences of all CA mutants were confirmed by sequencing performed by the Biopolymer Lab (University of Maryland, College Park, Md).
Transfection and infection procedures. Transfection of 293T and HeLa cells was performed by the calcium phosphate precipitation method as described previously (12). To generate virus particles capable of only a single round of replication, cells were cotransfected with parent or mutant pNL4-3KFS clones (10, 13) and pSV-A-MLVenv (33).
Replication kinetics were determined over an 8-week period using 5 × 106 CEM (12D7) cells transfected with 5 µg of pNL4-3 wild-type (2) or mutant DNA in the presence of 0.7 mg of DEAE-dextran/ml. The presence of virus particles in the supernatant fluids was determined by assay of exogenous RT activity (11). For single-cycle infections, cells were infected with pseudotyped virus particles, which were normalized for the amount of exogenous RT activity (106 cpm). Infectivity was measured in the MAGI assay, as described previously (29).Endogenous RT assay. Virions obtained by transfection of cells with pNL4-3KFS clones (10, 13) were normalized for exogenous RT activity (106 cpm) and were then pelleted at 14,000 × g for 90 min. The pellets were resuspended in 30 µl of a mixture containing the reaction components specified by Guo et al. (24) and were incubated for 16 h at 37°C. The samples were purified, denatured in 0.1 N NaOH at 37°C for 1 h, and subjected to electrophoresis in a 1% denaturing agarose gel (20 mM NaOH, 1 mM EDTA). The gels were dried and exposed to X-ray film.
For PCR analysis of the DNA products made in the endogenous reactions, the assay conditions were the same as those described above, except that all four deoxyribonucleoside triphosphates (dNTPs) (unlabeled) were added at a final concentration of 0.4 mM. Reaction products were diluted 1:1,000, and 1 µl of each dilution was used for PCR, as described below.PCR analysis of reverse transcription in acutely infected cells. Supernatant fluids from 293T cells cotransfected with pNL4-3KFS parent or mutant clones (10, 13) and pSV-A-MLVenv (33) were normalized for exogenous RT activity and were used to infect H9 cells (5 × 106 cpm [RT activity] per 106 H9 cells) for 3 h at 37°C. Cells were washed three times in phosphate-buffered saline (PBS), resuspended in 6 ml of growth medium, and incubated for 20 h at 37°C. After being washed with PBS, the cells were treated with 100 U of DNase I for 1 h at 37°C in the presence of 10 mM MgCl2. Proteinase K digestion and DNA extraction were performed using a QIAamp blood and tissue kit (Qiagen), as directed by the manufacturer. The DNA samples were treated with DpnI, which digests methylated plasmid DNA but which does not degrade unmethylated, newly synthesized viral DNA (56).
To eliminate any virus particles remaining on the cell surface, which could lead to contamination of the cell lysate with virion DNA, several changes in the previous procedure were made: (i) prior to infection, virus particles were incubated with 10 U of DNase I and 10 mM MgCl2 at 37°C for 30 min; (ii) CD4-positive HeLa indicator cells (rather than a suspension culture of H9 cells) were used for infection; and (iii) the cells were treated with a trypsin-EDTA solution to detach any bound virus particles (34) and were then washed two times with PBS before preparation of the cell lysate and extraction of DNA. Five hundred nanograms of each DNA preparation was used as the template for PCR with PCR SuperMix (Life Technologies). All samples were screened for contaminating pNL4-3 DNA by PCR amplification (3). None of the samples was found to contain contaminating plasmid DNA. To normalize for the quantity of total cellular DNA present in each sample, human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) DNA was amplified with forward primer JL416 (nucleotides [nt] 446 to 465) and reverse primer JL417 (nt 654 to 636) (46). Primers used to amplify viral DNA synthesized during the different steps of reverse transcription are as follows (note that the nucleotide positions correspond to the numbering in pNL4-3 [2]): (i) (
) SSDNA, forward primer JL405 (nt 454 to
477) and reverse primer JL406 (nt 635 to 612); (ii) DNA made after
minus-strand transfer, forward primer JL407 (nt 9028 to 9051) and
reverse primer JL408 (nt 9307 to 9288); (iii) 3' end of minus-strand
DNA, forward primer JL409 (nt 652 to 675) and reverse primer JL410 (nt
816 to 796); (iv) plus-strand strong-stop DNA [(+) SSDNA], forward primer JL405 and reverse primer JL411 (nt 653 to 635); (v) DNA made
after plus-strand transfer, forward primer JL405 and reverse primer
JL412 (nt 701 to 683); (vi) full-length double-stranded linear DNA,
forward primer JL434 (nt 251 to 274) and reverse primer JL412.
Two-long-terminal-repeat (2-LTR) circular DNA was detected by
"nested" PCR with outer primer set JL405 and JL433 (reverse primer
JL433, nt 9369 to 9349), followed by amplification with inner primer
set JL413 and JL408 (forward primer JL413, nt 597 to 621). PCR products
were separated by electrophoresis in nondenaturing 7.5% polyacrylamide
gels. The gels were stained with Vistra Green (Molecular Dynamics), and
the amount of DNA in each sample was quantified by PhosphorImager
analysis. Under our conditions,
500 or 1,000 copies of (
) SSDNA and
other DNA intermediates, respectively, can be detected.
Analysis of mutant and wild-type viral proteins. The procedures used for metabolic labeling of transfected HeLa cells with [35S]Cys, preparation of cell and virion lysates, and immunoprecipitation of labeled viral proteins and conditions for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) have been described previously (12, 26).
For Western blot analysis, the Western-Star chemiluminescence detection system (TROPIX Inc., Bedford, Mass.) was used. The following primary antibodies were used: rabbit anti-HIV CA sera (kindly provided by A. Ono, National Institute of Allergy and Infectious Diseases, National Institutes of Health [NIH], Bethesda, Md.), rabbit anti-HIV IN and RT peptide antisera (30), and AIDS patient sera (obtained from the NIH AIDS Research and Reference Reagent Program). The secondary antibodies were alkaline phosphatase-conjugated anti-rabbit immunoglobulin G (IgG) and anti-human IgG (TROPIX Inc.).Analysis of viral core morphology by transmission electron microscopy. Forty-eight hours posttransfection, 293T and HeLa cells transfected with pNL4-3KFS (10, 13) clones were washed twice with PBS and then fixed in situ with 1% paraformaldehyde and 3% glutaraldehyde for 2 h. The cells were scraped off the plate, further fixed with 2% OsO4 for 2 h, and then dehydrated with a graded series of ethanol dilutions ranging from 30 to 100% before they were embedded in Epon resin. Thin sections were counterstained with 1% lead citrate and 2% uranyl acetate before being examined by transmission electron microscopy.
| |
RESULTS |
|---|
|
|
|---|
Alanine substitution mutations in the N-terminal domain of CA.
A group of conserved hydrophobic residues faces the interior of the
coiled-coil-like structure formed by the five long
-helices in the
N-terminal domain of CA (38). To evaluate the role of these hydrophobic residues in HIV-1 replication, we made single alanine
substitutions in two aromatic residues, Trp23 (helix I, Fig. 1) and
Phe40 (helix II, Fig. 1), and introduced these mutations (i.e., W23A
and F40A) into the CA domain of Gag in the pNL4-3 infectious
clone of HIV-1 (2) and env-negative subclone
pNL4-3KFS (10, 13). We also constructed a mutant in which
Asp51 was changed to alanine (D51A). In earlier work (20,
51), it was shown that, in the mature CA protein, the
carboxylate of Asp51 forms a buried salt bridge with the charged amino
terminus of Pro1. The D51A mutation destroys this salt bridge and
unfolds the
-hairpin at the N terminus of CA.
The CA mutations do not impair virus particle production.
To
investigate the effect of the mutations on virus production and
release, HeLa cells or 293T cells were cotransfected with the pNL4-3KFS
clones and the pSV-A-MLVenv expression plasmid. Virus
particle production was determined by measuring the amount of RT
activity present in the supernatant fluids of the transfected cells
(11). None of the mutations had a major effect on virus release (Table 1). High-speed
sedimentation of the supernatant fluids of transfected cells indicated
that the RT activities could be recovered in the pellet fraction and
are therefore associated with virus particles (data not shown).
|
Composition of wild-type and mutant proteins in lysates of infected cells and in virions. Once it was established that virus particles are released into the supernatants (Table 1), it was of interest to determine whether the W23A, F40A, and D51A mutations affect the expression and incorporation of viral proteins. To approach this question, we transfected HeLa cells with the pNL4-3 wild-type or mutant clones and then metabolically labeled the proteins with [35S]Cys; cell- and virion-associated viral proteins were immunoprecipitated with AIDS patient serum and separated by gel electrophoresis (12, 26).
The results indicated that the protein patterns for the different mutants were largely similar to the wild-type viral protein profile (Fig. 2). As shown in Fig. 2A, the cell lysates all contained unprocessed Pr160gag-pol and Pr55gag, the Pr41gag cleavage intermediate, uncleaved envelope glycoprotein gp160, envelope protein gp120, and mature CA and MA proteins. Thus, the mutations introduced into CA did not interfere with the expression of viral proteins. Note, however, that with the exception of mature CA the proteins were expressed to a slightly greater extent for the mutant samples.
|
Endogenous RT activity is not inhibited by the three mutations in
CA.
To further characterize mutant virions and examine the
functionality of the encapsidated RT protein, we measured endogenous RT
activity in virions disrupted with 0.1% Nonidet P-40
(24). The results presented in Fig.
3A indicate that both wild-type and
mutant particles synthesized viral DNAs ranging in size from ~0.4 to
~2.5 kb, which appear as a smear in a denaturing agarose gel. A smear
of DNA products is typically observed in HIV endogenous RT assays
(21, 28) and contrasts with analogous MLV reactions, where
distinct species of full-length minus-strand and linear double-stranded
DNA products can be easily detected (37, 42). The data
also indicate that a somewhat higher level of total radioactive products was synthesized in the mutant samples.
|
) SSDNA, DNA made
after minus-strand transfer, (+) SSDNA, and DNA made after plus-strand
transfer were detected in wild-type and mutant reactions. In all cases,
no full-length linear DNA was observed, suggesting that the endogenous
reverse transcription reactions were not very efficient. (Note that in
the control reaction with pNL4-3KFS DNA [Fig. 3B, right lane] and in
cells infected with wild-type virus [Fig.
4A], full-length linear DNA could be readily detected.)
|

Replication kinetics and single-cycle infectivity of wild-type and mutant virions. Thus far, we have shown that the CA mutants produce virus particles that exhibit exogenous and endogenous RT activities and contain all of the viral proteins normally found in HIV-1 virions. One indication that mutant virions may not completely resemble wild-type particles comes from the observation that mutant CA proteins are reduced in amount and stability and the level of integrase is decreased (Fig. 2B). It was therefore important to determine whether the mutants are infectious.
To assay the mutants for infectivity in long-term culture experiments, CEM (12D7) cells were transfected with pNL4-3 wild-type and mutant clones. As expected, the wild-type virus replicated to high levels (Table 1), with virus production peaking on day 7 posttransfection and then declining with subsequent host cell death (data not shown). In contrast, there was no evidence of viral replication with any of the mutant viruses for up to 60 days in tissue culture (Table 1; data not shown). The infectivity of pNL4-3KFS pseudotyped virions was tested in the MAGI assay, which involves a single round of replication (29). In accord with the long-term culture experiment, none of the CA mutants showed any detectable infectivity (Table 1). To confirm these results, the W23A and D51A mutations were inserted into an HIV-1 molecular clone modified to express luciferase following infection (27). Consistent with the MAGI data, the single-cycle luciferase assay showed that luciferase expression could not be detected in the mutant samples (data not shown). Thus, using three different assays, we could establish that the CA mutations we have made lead to a complete loss of infectivity (i.e., a reduction of at least 3 log units relative to wild type). The data indicate that the loss of infectivity is not affected by the receptor that is utilized for viral entry, since the results were the same regardless of whether virus entry was mediated by the HIV-1 or MLV Env glycoproteins.The CA mutations impair the synthesis of viral DNA in newly infected cells. On the basis of the results from single-cycle infectivity assays, it appears as if the CA mutants are blocked at an early stage in virus replication. However, these assays cannot define which early step (e.g., reverse transcription, nuclear import, or integration) is affected. To approach this question, we used PCR to measure the amounts of viral DNA intermediates synthesized in newly infected H9 cells. To avoid the possibility that the Gag mutations might disrupt HIV-1 Env function at the level of virus entry and to increase the sensitivity of the assay, the infections were performed with pNL4-3KFS pseudotyped virions.
The primer sets used for this analysis were specific for the replication intermediates that are synthesized during the early and late stages of reverse transcription as well as for two-LTR circular DNA. Although this DNA is not a precursor to integrated DNA (reviewed in reference 4), it is found in the nuclei of infected cells after synthesis of linear double-stranded viral DNA; thus, the presence of the circular DNA is used as a marker for import of full-length viral DNA into the nucleus (4). The results of the PCR analysis are shown in Fig. 4. Figure 4A shows that the wild-type sample contained products corresponding to all of the intermediates that are normally synthesized during reverse transcription. In contrast, the samples from mutant virus-infected cells showed small amounts of (
) SSDNA and trace amounts of elongated minus-strand DNA and (+) SSDNA but no elongated plus-strand DNA, full-length DNA, or 2-LTR circular DNA. The identity of the (
) SSDNA
product was confirmed by Southern blot hybridization (data not shown).
Analysis of serially diluted samples indicated that the (
) SSDNA
product present in cells infected with the mutants was at least 20- to
50-fold less abundant than that present in wild-type virus-infected
cells (data not shown). These quantitative differences are not due to
differences in the amounts of total DNA in the samples, since
amplification of the hGAPDH cellular gene gave equivalent amounts of
product in each case.
Since a low level of reverse transcription can occur in HIV-1 virions
prior to infection (35, 47, 57, 58), it is entirely possible that the small amounts of (
) SSDNA detected in mutant virus-infected cells represent DNA synthesized in virus particles that
adhered to the cell surface at the time the cells were lysed and not
DNA synthesized following infection. To address this issue, CD4-positive HeLa indicator cells were infected with wild-type and
mutant viruses and were then trypsinized prior to extraction of DNA.
Under these conditions, PCR analysis showed that (
) SSDNA and DNA
made after minus-strand transfer were easily detected in DNA from
wild-type virus-infected cells, whereas neither of these two products
could be detected in samples from mutant virus-infected cells (Fig.
4B). These results demonstrate that the small amounts of DNA products
detected in mutant samples from untreated cells (Fig. 4A) are derived
from virions and are not the result of de novo DNA synthesis in
infected cells.
Thus, our findings indicate that virions bearing mutations that
substitute alanine for W23, F40, and D51 residues in the CA domain of Gag are unable to initiate reverse transcription in the
infected cell. This defect is unrelated to any effect of the mutations
on RT itself, since mutant and wild-type particles exhibit similar
levels of endogenous (Fig. 3) and exogenous (Table 1) RT activities.
Electron-microscopic analysis shows aberrant morphology of
mutant virions.
Since some studies have indicated a link between
viral DNA synthesis postentry and proper maturation of the viral core
(7, 39), it was of great interest to examine the effect of
the three CA mutations on virion morphology and core structure. 293T
and HeLa cells transfected with the pNL4-3KFS clones were examined by
transmission electron microscopy (Fig.
5). An example of a wild-type particle
with the typical cone-shaped core is shown in Fig. 5A; particles with
centric or acentric cores were also present in the wild-type virus
population (Fig. 5B). (An acentric core is defined as an
electron-dense, round core that is pushed up against a small region of
the viral membrane; a centric core is also round and electron dense but
is centrally located in the particle). Mutants D51A (Fig. 5C and D) and
F40A (Fig. 5E) exhibited only centric or acentric cores and no conical
cores. The absence of a conical core in D51A virions has also been
noted by von Schwedler et al. (51). Analysis of the W23A
particles revealed gross abnormalities (Fig. 5F). No particles with a
defined core could be detected; in addition, W23A particles had unusual
shapes, with a layer of what is probably the Gag protein lining the
inner surface of the viral membrane. Figure 5F shows one of the
abnormal particles budding from the cell membrane.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In the present study, our goal was to investigate the effect of
single-alanine-substitution mutations of several conserved residues in
the N-terminal domain of the HIV-1 CA protein on the ability of virions
to undergo reverse transcription in the infected cell. The mutated
amino acids included (i) Trp23 and Phe40, two representative members of
a group of highly conserved hydrophobic residues (Fig. 1)
(38) that has been suggested to be important for
maintaining the stability of the CA structure and functional activity,
and (ii) Asp51, another highly conserved residue that forms a buried
salt bridge with Pro1 in the mature CA protein (20, 51).
Here, we report that, while the mutations have little effect on in
vitro RT activities, the mutants are severely impaired in the
initiation of viral DNA synthesis in infected cells and do not make
detectable amounts of viral DNA products, including (
) SSDNA.
To correlate the RT results with other parameters of viral infection, we also examined (i) virus particle production, (ii) infectivity, (iii) viral proteins present in lysates of infected cells and in virions, (iv) endogenous reverse transcription, and (v) virion core morphology. The three mutations do not have a major effect on production of virus particles (Table 1), but mutant virions are not infectious in single-cycle and long-term infectivity assays (Table 1). These findings are consistent with what has been observed for other N-terminal domain mutants and support the conclusion that this domain is not involved in particle release but is required for infectivity (5, 7, 40, 51, 52).
The mutants express all of the normal intracellular and virion-associated viral proteins (Fig. 2). The amount of Pr55gag is increased in lysates of mutant virus-infected cells, but the amount of intracellular CA is reduced. Similarly, reduced amounts of CA are present in mutant particles. The decrease in CA is correlated with lowered stability of the mutant CA proteins, as shown by the appearance of CA-related bands that are smaller than p24 (Fig. 2B) (51). Reduction in the level of CA protein has also been found in studies of other HIV-1 N-terminal CA mutants (5, 7, 40). The finding that mutant particles contain decreased amounts of IN (Fig. 2B) is surprising and has not been previously reported for virions with N-terminal CA mutations. Although no evidence for IN degradation was detected by Western blot analysis (data not shown), it is possible that the CA mutations may destabilize the core, thereby leading to a loss or instability of IN.
Examination of mutant virions, produced in either HeLa or 293T cells, by transmission electron microscopy indicated that they exhibit a phenotype that differs from that of wild-type particles. The population of wild-type virions contained a significant number of cone-shaped cores as well as approximately equal proportions of centric and acentric cores (Fig. 5A and B; Table 2); the appearance of conical or round cores depends on whether the plane of sectioning was vertical or horizontal. In contrast, no conical cores could be detected in any of the mutant virus samples (Table 2). We found that the majority of F40A and D51A particles have an acentric core, with only a small percentage containing centric cores (Fig. 5C, D, and E; Table 2) (51). Mutant W23A has an unusual phenotype: these virions seem unable to assemble recognizable mature particles and instead produce immature virions of varied size and shape, which appear to have a protein (presumably Gag) lining the inner surface (Fig. 5F). This is a rather striking effect on virus assembly, particularly since it results from mutation of a single residue.
Based on studies performed thus far, two different classes of N-terminal CA mutants can be distinguished. For example, previous reports on the properties of virions with mutations in the CypA loop (3, 7) indicate that these particles contain normal cores but are defective in reverse transcription. Although the mutants synthesize some viral DNA in infected cells, including in most cases full-length DNA, the amount is reduced with respect to that made by wild-type virus; moreover, no 2-LTR circular DNA can be detected, possibly because the full-length DNA product cannot enter the nucleus or the ends are abnormal and cannot be amplified.
Other N-terminal CA mutants that have defects in reverse transcription
and in core condensation and that are more similar to the class of
mutants in this study have been described. For example, in work on
N-terminal CA linker insertion mutants, it was found that virions
containing only round cores do not synthesize 2-LTR circular DNA
(39). However, since synthesis of early DNA intermediates
was not evaluated, it is not possible to determine at which step
reverse transcription was blocked. Another example is a P1L mutant that
lacks a cone-shaped core and that does not synthesize a vif
DNA product, indicative of partial elongation of minus-strand DNA;
synthesis of (
) SSDNA was not measured (7). In view of
the fact that Pro1 forms a buried salt bridge with Asp51 (20,
51), it is not surprising that P1L virions have a phenotype
similar to that of D51A (Fig. 4 and 5) (51).
Here, we demonstrate that the W23A, F40A, and D51A mutants, which do
not produce any particles with conical cores, are profoundly compromised in their ability to initiate reverse transcription in
infected cells (Fig. 4B). Thus, by treating infected cells with trypsin
to remove virions adhering to the cell surface, we could clearly
establish that none of the mutants makes any detectable (
) SSDNA
(compare Fig. 4A and B). We have also made five additional mutants with
alanine substitutions at the conserved hydrophobic residues
(38) including L20A (helix I), L52A (helix III), M55A (helix III), V59A (helix III), and L138A (helix VII). Preliminary results indicate that these mutants exhibit abnormal core structures and are also unable to initiate reverse transcription postinfection (our unpublished observations).
It should be noted that, while all of the alanine substitution mutants
we have made are blocked in synthesis of (
) SSDNA in infected cells
(Fig. 4B) (our unpublished observations), they make somewhat larger
amounts of total DNA than wild-type virions in endogenous assays (Fig.
3A) (our unpublished observations). This may reflect a more "open"
core structure in these mutants, which could allow more efficient
penetration of dNTPs into the particle.
It is of interest to speculate on the explanation for the phenotype of the mutants described in this study. Taken together, our findings are consistent with a defect in core stability or in a postentry step that precedes reverse transcription. An investigation of the stability of the mutant cores has been initiated. An alternate possibility that there is a defect in viral entry appears to be less likely: Thus, to assay DNA synthesis in infected cells, virions pseudotyped with an MLV envelope were used (Fig. 4); this route bypasses the normal gp120-dependent mode of HIV-1 entry.
In conclusion, we have demonstrated a crucial connection between the ability of virus particles to carry out reverse transcription in infected cells and virion core morphology. We propose the existence of classes of N-terminal CA mutants which differ in the severity of individual mutations with respect to core structure and the extent to which DNA synthesis is inhibited. Two such classes can already be identified. The particular class of mutants analyzed in this and some other (7, 39) studies has an extreme phenotype. In this case, a profound deficiency in reverse transcription postentry appears to be predictive of a prior defect in core maturation during virus assembly.
| |
ACKNOWLEDGMENTS |
|---|
We thank Kunio Nagashima for expert assistance with the electron microscopy, Brenda Soto for outstanding help with cloning, Akira Ono for a gift of anti-CA serum, Zhonglin Yang for generating the ribbon diagram illustrating the structure of the N-terminal CA domain, and Alan Rein for critical reading of the manuscript.
This work was supported in part by funds from the National Institutes of Health Intramural AIDS Targeted Antiviral Program awarded to J.G.L.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratory of Molecular Genetics, NICHD, Building 6B, Room 216, NIH, Bethesda, MD 20892-2780. Phone: (301) 496-1970. Fax: (301) 496-0243. E-mail: jlevin{at}mail.nih.gov.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Accola, M. A.,
Å. Öhagen, and H. G. Göttlinger.
2000.
Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6gag.
J. Virol.
74:6198-6202 |
| 2. |
Adachi, A.,
H. E. Gendelman,
S. Koenig,
T. Folks,
R. Willey,
A. Rabson, and M. A. Martin.
1986.
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
J. Virol.
59:284-291 |
| 2a. | Alin, K., and S. P. Goff. 1996. Amino acid substitutions in the CA protein of Moloney murine leukemia virus that block early events in infection. Virology 222:339-351[CrossRef][Medline]. |
| 2b. |
Bowzard, J. B.,
J. W. Wills, and R. C. Craven.
2001.
Second-site suppressors of Rous sarcoma virus CA mutations: evidence for interdomain interactions.
J. Virol.
75:6850-6856 |
| 3. | Braaten, D., E. K. Franke, and J. Luban. 1996. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J. Virol. 70:3551-3560[Abstract]. |
| 4. | Brown, P. O. 1997. Integration, p. 161-203. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 4a. |
Cairns, T. M., and R. C. Craven.
2001.
Viral DNA synthesis defects in assembly-competent Rous sarcoma virus CA mutants.
J. Virol.
75:242-250 |
| 5. |
Dorfman, T.,
A. Bukovsky,
Å. Öhagen,
S. Höglund, and H. G. Göttlinger.
1994.
Functional domains of the capsid protein of human immunodeficiency virus type 1.
J. Virol.
68:8180-8187 |
| 6. |
Feng, Y. X.,
T. D. Copeland,
L. E. Henderson,
R. J. Gorelick,
W. J. Bosche,
J. G. Levin, and A. Rein.
1996.
HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro.
Proc. Natl. Acad. Sci. USA
93:7577-7581 |
| 7. | Fitzon, T., B. Leschonsky, K. Bieler, C. Paulus, J. Schröder, H. Wolf, and R. Wagner. 2000. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology 268:294-307[CrossRef][Medline]. |
| 8. | Franke, E. K., H. E. Yuan, and J. Luban. 1994. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359-362[CrossRef][Medline]. |
| 9. | Freed, E. O. 1998. HIV-1 Gag proteins: diverse functions in the virus life cycle. Virology 251:1-15[CrossRef][Medline]. |
| 10. |
Freed, E. O.,
E. L. Delwart,
G. L. Buchschacher, Jr., and A. T. Panganiban.
1992.
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.
Proc. Natl. Acad. Sci. USA
89:70-74 |
| 11. | Freed, E. O., G. Englund, and M. A. Martin. 1995. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J. Virol. 69:3949-3954[Abstract]. |
| 12. |
Freed, E. O., and M. A. Martin.
1994.
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120.
J. Virol.
68:2503-2512 |
| 13. | Freed, E. O., and M. A. Martin. 1995. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J. Virol. 69:1984-1989[Abstract]. |
| 14. |
Fu, W.,
R. J. Gorelick, and A. Rein.
1994.
Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions.
J. Virol.
68:5013-5018 |
| 15. |
Fu, W., and A. Rein.
1993.
Maturation of dimeric viral RNA of Moloney murine leukemia virus.
J. Virol.
67:5443-5449 |
| 16. | Gamble, T. R., F. F. Vajdos, S. Yoo, D. K. Worthylake, M. Houseweart, W. I. Sundquist, and C. P. Hill. 1996. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87:1285-1294[CrossRef][Medline]. |
| 17. |
Gamble, T. R.,
S. Yoo,
F. F. Vajdos,
U. K. von Schwedler,
D. K. Worthylake,
H. Wang,
J. P. McCutcheon,
W. I. Sundquist, and C. P. Hill.
1997.
Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein.
Science
278:849-853 |
| 18. |
Ganser, B. K.,
S. Li,
V. Y. Klishko,
J. T. Finch, and W. I. Sundquist.
1999.
Assembly and analysis of conical models for the HIV-1 core.
Science
283:80-83 |
| 19. | Gelderblom, H. R. 1991. Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 5:617-637[Medline]. |
| 20. | Gitti, R. K., B. M. Lee, J. Walker, M. F. Summers, S. Yoo, and W. I. Sundquist. 1996. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science 273:231-235[Abstract]. |
| 21. | Goncalves, J., Y. Korin, J. Zack, and D. Gabuzda. 1996. Role of Vif in human immunodeficiency virus type 1 reverse transcription. J. Virol. 70:8701-8709[Abstract]. |
| 22. |
Gross, I.,
H. Hohenberg,
C. Huckhagel, and H. G. Kräusslich.
1998.
N-terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles.
J. Virol.
72:4798-4810 |
| 23. | Gross, I., H. Hohenberg, T. Wilk, K. Wiegers, M. Grättinger, B. Müller, S. Fuller, and H. G. Kräusslich. 2000. A conformational switch controlling HIV-1 morphogenesis. EMBO J. 19:103-113[CrossRef][Medline]. |
| 24. | Guo, J., L. E. Henderson, J. Bess, B. Kane, and J. G. Levin. 1997. Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA. J. Virol. 71:5178-5188[Abstract]. |
| 25. |
Henderson, L. E.,
M. A. Bowers,
R. C. Sowder II,
S. A. Serabyn,
D. G. Johnson,
J. W. Bess, Jr.,
L. O. Arthur,
D. K. Bryant, and C. Fenselau.
1992.
Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.
J. Virol.
66:1856-1865 |
| 26. | Huang, M., J. M. Orenstein, M. A. Martin, and E. O. Freed. 1995. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69:6810-6818[Abstract]. |
| 27. |
Kiernan, R. E.,
A. Ono,
G. Englund, and E. O. Freed.
1998.
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.
J. Virol.
72:4116-4126 |
| 28. |
Kiernan, R. E.,
A. Ono, and E. O. Freed.
1999.
Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.
J. Virol.
73:4728-4737 |
| 29. |
Kimpton, J., and M. Emerman.
1992.
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated -galactosidase gene.
J. Virol.
66:2232-2239 |
| 30. | Klutch, M., A. M. Woerner, C. J. Marcus-Sekura, and J. G. Levin. 1998. Generation of HIV-1/HIV-2 cross-reactive peptide antisera by small sequence changes in HIV-1 reverse transcriptase and integrase immunizing peptides. J. Biomed. Sci. 5:192-202[CrossRef][Medline]. |
| 31. |
Kotov, A.,
J. Zhou,
P. Flicker, and C. Aiken.
1999.
Association of Nef with the human immunodeficiency virus type 1 core.
J. Virol.
73:8824-8830 |
| 32. | Kraulis, P. J. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:946-950[CrossRef]. |
| 33. |
Landau, N. R.,
K. A. Page, and D. R. Littman.
1991.
Pseudotyping with human T-cell leukemia virus type 1 broadens the human immunodeficiency virus host range.
J. Virol.
65:162-169 |
| 34. |
Levin, J. G.,
P. M. Grimley,
J. M. Ramseur, and I. K. Berezesky.
1974.
Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D.
J. Virol.
14:152-161 |
| 35. |
Lori, F.,
F. di Marzo Veronese,
A. L. de Vico,
P. Lusso,
M. S. Reitz, Jr., and R. C. Gallo.
1992.
Viral DNA carried by human immunodeficiency virus type 1 virions.
J. Virol.
66:5067-5074 |
| 36. |
Mervis, R. J.,
N. Ahmad,
E. P. Lillehoj,
M. G. Raum,
F. H. R. Salazar,
H. W. Chan, and S. Venkatesan.
1988.
The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.
J. Virol.
62:3993-4002 |
| 37. | Messer, L. I., K. M. Currey, B. J. O'Neill, J. V. Maizel, Jr., J. G. Levin, and B. I. Gerwin. 1985. Functional analysis of reverse transcription by a frameshift pol mutant of murine leukemia virus. Virology 146:146-152[CrossRef][Medline]. |
| 38. | Momany, C., L. C. Kovari, A. J. Prongay, W. Keller, R. K. Gitti, B. M. Lee, A. E. Gorbalenya, L. Tong, J. McClure, L. S. Ehrlich, M. F. Summers, C. Carter, and M. G. Rossmann. 1996. Crystal structure of dimeric HIV-1 capsid protein. Nat. Struct. Biol. 3:763-770[CrossRef][Medline]. |
| 39. | Reicin, A. S., A. Ohagen, L. Yin, S. Hoglund, and S. P. Goff. 1996. The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J. Virol. 70:8645-8652[Abstract]. |
| 40. | Reicin, A. S., S. Paik, R. D. Berkowitz, J. Luban, I. Lowy, and S. P. Goff. 1995. Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J. Virol. 69:642-650[Abstract]. |
| 41. | Rein, A., L. E. Henderson, and J. G. Levin. 1998. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem. Sci. 23:297-301[CrossRef][Medline]. |
| 42. | Rothenberg, E., D. Smotkin, D. Baltimore, and R. A. Weinberg. 1977. In vitro synthesis of infectious DNA of murine leukaemia virus. Nature 269:122-126[CrossRef][Medline]. |
| 43. | Swanstrom, R., and J. W. Wills. 1997. Synthesis, assembly, and processing of viral proteins, p. 263-334. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 44. |
Tang, S.,
A. J. Collier, and R. M. Elliott.
1999.
Alterations to both the primary and predicted secondary structure of stem-loop IIIc of the hepatitis C virus 1b 5' untranslated region (5'UTR) lead to mutants severely defective in translation which cannot be complemented in trans by the wild-type 5'UTR sequence.
J. Virol.
73:2359-2364 |
| 45. | Thali, M., A. Bukovsky, E. Kondo, B. Rosenwirth, C. T. Walsh, J. Sodroski, and H. G. Göttlinger. 1994. Functional association of cyclophilin A with HIV-1 virions. Nature 372:363-365[CrossRef][Medline]. |
| 46. |
Tokunaga, K.,
Y. Nakamura,
K. Sakata,
K. Fujimori,
M. Ohkubo,
K. Sawada, and S. Sakiyama.
1987.
Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers.
Cancer Res.
47:5616-5619 |
| 47. |
Trono, D.
1992.
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses.
J. Virol.
66:4893-4900 |
| 48. | Turner, B. G., and M. F. Summers. 1999. Structural biology of HIV. J. Mol. Biol. 285:1-32[CrossRef][Medline]. |
| 49. | Vogt, V. M. 1997. Retroviral virions and genomes, p. 27-69. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 50. |
Vogt, V. M., and M. N. Simon.
1999.
Mass determination of Rous sarcoma virus virions by scanning transmission electron microscopy.
J. Virol.
73:7050-7055 |
| 51. | von Schwedler, U. K., T. L. Stemmler, V. Y. Klishko, S. Li, K. H. Albertine, D. R. Davis, and W. I. Sundquist. 1998. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J. 17:1555-1568[CrossRef][Medline]. |
| 52. |
Wang, C. T., and E. Barklis.
1993.
Assembly, processing, and infectivity of human immunodeficiency virus type 1 Gag mutants.
J. Virol.
67:4264-4273 |
| 53. |
Welker, R.,
H. Hohenberg,
U. Tessmer,
C. Huckhagel, and H. G. Kräusslich.
2000.
Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1.
J. Virol.
74:1168-1177 |
| 54. | Wiegers, K., G. Rutter, U. Schubert, M. Grättinger, and H. G. Kräusslich. 1999. Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. Virology 257:261-274[CrossRef][Medline]. |
| 55. | Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral Gag proteins. AIDS 5:639-654[Medline]. |
| 56. |
Wu, X.,
H. Liu,
H. Xiao,
J. A. Conway,
E. Hehl,
G. V. Kalpana,
V. Prasad, and J. C. Kappes.
1999.
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex.
J. Virol.
73:2126-2135 |
| 57. |
Zack, J. A.,
A. M. Haislip,
P. Krogstad, and I. S. Chen.
1992.
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.
J. Virol.
66:1717-1725 |
| 58. | Zhang, H., Y. Zhang, T. Spicer, D. Henrard, and B. J. Poiesz. 1995. Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle. J. Virol. 69:3675-3682[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»